Biogen (BIIB) Net Income towards Common Stockholders (2009 - 2026)

Biogen's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $319.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
• Net Income towards Common Stockholders was $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.1 billion in Q3 2022 to a low of -$64.2 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged $437.3 million across 5 years, with a median of $393.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 948.37% in 2022, then tumbled 118.34% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $559.0 million in 2022, then plunged by 55.47% to $248.9 million in 2023, then advanced by 7.15% to $266.7 million in 2024, then sank by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $319.5 million (Q1 2026), -$48.9 million (Q4 2025), and $466.5 million (Q3 2025), per Business Quant data.